SCHEMBL973964

SCHEMBL973964

[c]1nc2cccnn2n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068982 0.64
SCHEMBL130057 0.62
SCHEMBL305773 0.62
SCHEMBL976956 0.61
SCHEMBL8145093 0.60 DYRK1A (0.34)
SCHEMBL858847 0.59
SCHEMBL130376 0.58
SCHEMBL1277170 0.56
SCHEMBL976783 0.56
SCHEMBL21672400 0.56 CDK4 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4352055-A1 O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2024-04-17 EP claimed
WO-2022259204-A1 O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2022-12-15 WO claimed
US-11382918-B2 Methods for treating Huntington's Disease PTC THERAPEUTICS, INC. (US) 2022-07-12 US claimed
US-20210284660-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2021-09-16 US claimed
EP-3814345-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2021-05-05 EP claimed
US-20200163973-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2020-05-28 US claimed
US-20200147087-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2020-05-14 US claimed
EP-3644996-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2020-05-06 EP claimed
EP-3645121-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2020-05-06 EP claimed
WO-2019005980-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2019-01-03 WO claimed
WO-2019005993-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2019-01-03 WO claimed
EP-4352055-A1 O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2024-04-17 EP disclosed
EP-4308576-A1 NEW THIAZOLOPYRIMIDINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-01-24 EP disclosed
EP-4308577-A1 NEW THIADIAZOLOPYRIMIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-01-24 EP disclosed
EP-4308572-A1 NEW THIENOPYRIMIDINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-01-24 EP disclosed
WO-2019005980-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2019-01-03 WO disclosed
WO-2019005993-A1 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2019-01-03 WO disclosed
EP-2235016-B1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-09-18 EP disclosed
US-8394820-B2 N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 US disclosed
US-20110009444-A1 N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US disclosed